share_log

榮昌生物：海外監管公告 - 第二屆監事會第九次會議決議公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:12
Summary by Moomoo AI
荣昌生物制药（煙台）股份有限公司於2024年3月29日召開第二屆監事會第九次會議，會議決議通過了向特定對象發行A股股票的相關議案。本次發行的股票數量不超過公司總股本的13%，即不超過70,763,170股。發行對象為不超過35名特定投資者，包括符合條件的證券投資基金管理公司、證券公司、信托公司等。發行股票將在上海證券交易所科創板上市交易，並將募集資金主要用於新藥研發項目。本次發行的有效表決票均為同意票，且議案尚需提交股東大會審議。會議的召集、召開及表決程序符合相關法律法規，所作決議合法有效。
荣昌生物制药（煙台）股份有限公司於2024年3月29日召開第二屆監事會第九次會議，會議決議通過了向特定對象發行A股股票的相關議案。本次發行的股票數量不超過公司總股本的13%，即不超過70,763,170股。發行對象為不超過35名特定投資者，包括符合條件的證券投資基金管理公司、證券公司、信托公司等。發行股票將在上海證券交易所科創板上市交易，並將募集資金主要用於新藥研發項目。本次發行的有效表決票均為同意票，且議案尚需提交股東大會審議。會議的召集、召開及表決程序符合相關法律法規，所作決議合法有效。
RONG CHANG BIOPHARMACEUTICALS (YANTAI) CO., LTD. HELD THE NINTH MEETING OF THE SECOND SUPERVISORY BOARD ON MARCH 29, 2024, AND THE MEETING RESOLVED TO ISSUE A SHARES TO A SPECIFIC AUDIENCE. The number of shares issued in this year does not exceed 13% of the total share capital of the company, i.e. not more than 70,763,170 shares. Issuers are addressed to no more than 35 specific investors, including qualifying investment fund management companies, securities firms, trust companies, etc. The issued shares will be listed on the Shanghai Stock Exchange's Sci-Tech Board and will raise funds primarily for new drug R&D projects. Valid votes issued in this issuance are consents and are subject to submission to the General Meeting for consideration. The convening, holding and voting procedures of the meetings are in accordance with the relevant laws and regulations, and the decisions taken are legally valid.
RONG CHANG BIOPHARMACEUTICALS (YANTAI) CO., LTD. HELD THE NINTH MEETING OF THE SECOND SUPERVISORY BOARD ON MARCH 29, 2024, AND THE MEETING RESOLVED TO ISSUE A SHARES TO A SPECIFIC AUDIENCE. The number of shares issued in this year does not exceed 13% of the total share capital of the company, i.e. not more than 70,763,170 shares. Issuers are addressed to no more than 35 specific investors, including qualifying investment fund management companies, securities firms, trust companies, etc. The issued shares will be listed on the Shanghai Stock Exchange's Sci-Tech Board and will raise funds primarily for new drug R&D projects. Valid votes issued in this issuance are consents and are subject to submission to the General Meeting for consideration. The convening, holding and voting procedures of the meetings are in accordance with the relevant laws and regulations, and the decisions taken are legally valid.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more